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Background: We investigated the feasibility of dose-dense neoadjuvant chemotherapy (NACT) with paclitaxel and carboplatin
before radical chemoradiation (CRT) and assessed the response rate to such a regimen.
Methods: CxII is a single-arm phase II trial of 46 patients, with locally advanced cervical cancer (stage Ib2-IVa). Patients received
dose-dense carboplatin (AUC2) and paclitaxel (80mgm 2) weekly for six cycles followed by CRT (40mgm 2 of weekly cisplatin,
50.4Gy, 28 fractions plus brachytherapy). The primary end point was response rate 12 weeks post-CRT.
Results: Baseline characteristics were: median age at diagnosis 43 years; 72% squamous, 22% adenocarcinoma and 7%
adenosquamous histologies; FIGO stage IB2 (11%), II (50%), III (33%), IV (7%). Complete or partial response rate was 70% (95% CI:
54–82) post-NACT and 85% (95% CI: 71–94) post-CRT. The median follow-up was 39.1 months. Overall and progression-free
survivals at 3 years were 67% (95% CI: 51–79) and 68% (95% CI: 51–79), respectively. Grade 3/4 toxicities were 20% during NACT
(11% haematological, 9% non-haematological) and 52% during CRT (haematological: 41%, non-haematological: 22%).
Conclusion: A good response rate is achieved by dose-dense weekly NACT with carboplatin and paclitaxel followed by radical
CRT. This treatment regimen is feasible as evidenced by the acceptable toxicity of NACT and by the high compliance to
radiotherapy (98%).
Despite the fall in incidence of cervical cancer in countries with a
screening programme, a large proportion of those diagnosed with
invasive cancer have locally advanced disease at presentation. An
audit by the Royal College of Radiologists in 2001–2002, of UK
patients with cervical cancer treated non-surgically with curative
intent, found a 5-year survival rate of 56% (Vale et al, 2010).
Chemoradiation (CRT) has been the standard of care since 1999
(Keys et al, 1999; Morris et al, 1999; Whitney et al, 1999), and
was widely adopted in the UK (McCormack et al, 2001). An
individual patient data meta-analysis based on 18 trials from 11
countries confirmed the benefit of CRT. However, the estimated
improvement in a 5-year overall survival (OS) was only 6%
(i.e., from 60 to 66%, HR: 0.81), with a disease-free survival rate
of 58% (CCCMAC - Chemoradiotherapy for Cervical Cancer
Meta-analysis Collaboration, 2008). The benefit of adding
chemotherapy to radiotherapy was seen regardless of age, histology
and grade, but appeared to be lower in patients with more
advanced tumours. In the decade since the introduction of CRT,
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there have been no further advances in the management of locally
advanced cervical cancer. A single trial has reported a survival
advantage with accent on n and a from the addition of adjuvant
chemotherapy after CRT (Duen˜as-Gonza´lez et al, 2011), but
further randomised trials are required.
The role of neoadjuvant chemotherapy (NACT) has been
examined in a number of trials. Although a meta-analysis of 21
randomised trials showed no improvement in OS with NACT,
there was an association between outcome and short cycle length,
or platinum with a dose intensity of more than 25mgm 2 per
week (NCLACCM - Neoadjuvant Chemotherapy for Locally
Advanced Cervical Cancer Meta-analysis Collaboration, 2003).
Trials with a cycle length of p14 days were associated with an
improvement in OS of approximately 7% at 5 years, whereas longer
cycle lengths had a detrimental effect on outcome.
The combination of taxane and platinum is known to be active
in advanced and recurrent cervical cancer with response rates of
40–50% (Papadimitriou et al, 1999; Rose et al, 1999). This
combination is also active in the neoadjuvant accent on n and a
setting with reported response rates of up to 90–95% (Duen˜as-
Gonza´lez et al, 2003; Park et al, 2004). Cisplatin and paclitaxel
requires a longer infusion compared with carboplatin/paclitaxel
combination, which is demonstrated to have acceptable toxicity
and promising activity (Tinker et al, 2005; Moore et al, 2007;
Mabuchi et al, 2010). We therefore postulated that a short course
of weekly dose-dense paclitaxel and carboplatin chemotherapy
before CRT might downstage local disease, lengthen the exposure
to systemic treatment and improve outcome. This trial (called
CXII) investigated the feasibility of NACT and assessed the overall
response rate after the doublet chemotherapy and at 12 weeks after
the completion of CRT.
MATERIALS AND METHODS
We conducted a single-arm phase II trial in women with locally
advanced cervical cancer treated with neoadjuvant weekly
paclitaxel and carboplatin chemotherapy followed immediately
by concomitant CRT.
Study population and eligibility criteria. Patients, 18 years or
older, with histological confirmation of squamous, adeno- or
adenosquamous carcinoma of the cervix, FIGO stage Ib2-IVa who
were suitable for radical CRT were eligible to participate. This
included patients with histologically positive para-aortic lymph
nodes (PALN). All patients had a biopsy, examination under
anaesthetic (EUA) and imaging to complete the staging as detailed
below. Patients were required to have an ECOG performance status
0–1; adequate renal function (glomerular filtration rate
X60mlmin 1 measured isotopically or by creatinine clearance);
adequate liver function (ALT or AST o2.5 ULN, and bilirubin
o1.25 ULN); adequate bone marrow function (WCC 43.0 109
per l, neutrophils41.5 109 per l and platelets4100 109 per l);
and a normal ECG. Patients with a hydronephrosis had a ureteric
stent inserted regardless of renal function. Patients were excluded if
they were pregnant or breast feeding, had a previous diagnosis of
cancer except basal cell carcinoma, or had active cardiac disease.
Ethics and regulatory approvals were obtained, and all patients
gave written informed consent. Cervical tumour tissue samples
were collected for future translational studies.
Treatment schedule. Neoadjuvant chemotherapy was given
weekly for 6 weeks (on days 1, 8, 15, 22, 29 and 36) as follows:
paclitaxel (80mgm 2) over 1 h, followed by carboplatin (AUC
2- dose calculated by Calvert formula) over 30min. Dose
modifications were allowed for haematological toxicity. Both drugs
were omitted on any week if neutrophils were o1.0 109 per l or
plateletso75 109 per l on the day of treatment. In all subsequent
cycles, paclitaxel was then given at 85% of full dose and carboplatin
at AUC 1.6. In the event of further haematological toxicity NACT
was discontinued. Patients with a significant hypersensitivity
reaction to paclitaxel were withdrawn from the study, whereas
those with a reaction to carboplatin were allowed to continue on
paclitaxel alone. The glomerular filtration rate was repeated and
carboplatin dose recalculated if there was a 10% rise in serum
creatinine on up to two consecutive tests or if the serum creatinine
became abnormal for the first time. Paclitaxel was stopped if
patients experienced Xgrade 2 peripheral neuropathy. If NACT
was discontinued early, patients proceeded to radiation and
cisplatin was commenced when blood counts had recovered.
Radiation, following NACT, began on week 7 with concomitant
cisplatin (CRT) commencing as soon as haematological recovery
permitted. Cisplatin (40mgm 2, maximum 70mg) was given with
hydration over 1 h (before radiation), weekly for a minimum of
four cycles and maximum of six cycles. Radiotherapy to the whole
pelvis was given to a total dose of 50.4 Gy in 28 fractions over 5.5
weeks using 8–15mV photons. Intracavitary brachytherapy was
given towards the end of or following completion of external beam
radiation. Patients received a total dose of 15Gy in two fractions to
point A HDR or an equivalent dose using LDR (25Gy to point A).
The external beam radiation to the pelvis was delivered using a
four-field (AP/PA and two lateral fields) arrangement. The conven-
tional pelvic field extended from the top of L5 to the bottom of the
obturator foramen or 2 cm below the lowest level of disease and
laterally 1.5 cm beyond the bony pelvis. The lateral fields extended
from the anterior border of the symphysis pubis to the S2/3
interspace posteriorly. However, fields were modified to take account
of available information from pre-treatment MRI scans and EUA to
ensure adequate tumour coverage. Shielding of the corners of AP/PA
field was permitted. Where extended fields were used to treat PALN
the superior field border was at T12/L1 and the inferior border at L4/
5. This PALN strip was treated using an AP/PA field to a dose of
45Gy in 25 fractions over 5 weeks. In patients with parametrial
involvement or pelvic sidewall extension, a boost was permitted to a
dose of 5.4Gy in three fractions over 3 days using AP/PA fields. Every
effort was made to ensure that the entire course of radiotherapy was
completed within 50 days, and that the haemoglobin level was
maintained at X12.5 g dl 1 throughout the CRT.
Assessments. At baseline, all patients had an X-ray or CT of the
chest and CT or MRI scan of the abdomen (within the previous
6 weeks), and an MRI of the pelvis. Full blood counts were
performed weekly during NACT and twice weekly during CRT.
Biochemistry and toxicity assessments were carried out weekly
during treatment, then 4 weeks post-CRT and 3-monthly for 2
years. Severity of adverse events was categorised using NCI CTCAE
version 3.0. Specific radiotherapy toxicities were classified accord-
ing to RTOG criteria (Cox et al, 1995).
A pelvic MRI was performed at the end of the sixth week of
NACT to assess response using RECIST criteria (Therasse et al,
2000). Overall response was determined using pelvic MRI 12 weeks
after the completion of CRT. MRI scans were reviewed centrally at
UCL Hospitals. Further radiological assessments were conducted
as clinically indicated.
Statistical considerations. The primary end point was the
response rate 12 weeks after completing all treatment. The target
response rate was X85% and no lower than 70% (which could be
achieved with current practice). This required approximately 50
patients, with 80% power and a 5% one-sided test of statistical
significance. The response rate to NACT was also assessed. Overall
and progression-free survivals (PFSs) were measured from the date
of study registration until progression, death from any cause or the
date last seen alive. Adverse events were based on the maximum
toxicity grade for each type of event. All analyses were intention-
to-treat.
A phase II study of weekly NACT followed by CRT BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.230 2465
RESULTS
Patient demographics. A total of 46 patients were recruited from
three centres in London, Leicester and Birmingham between June
2005 and October 2008, with median follow-up of 39.1 months.
Baseline characteristics are shown in Table 1. The median age was 43
years and 72% had squamous cell cancers. The majority of the cases
were either FIGO stage IIb (50%) or IIIb (28%). In all, 11% (5/46)
had positive PALN, 3 in FIGO IIb group and 2 in FIGO IIIb group.
Treatment compliance. Eighty percent of patients (37/46)
completed all six cycles of NACT, 13% had a dose delay and 9%
a dose reduction (Table 2). Forty-two patients (91%) had full doses
of drugs for at least four cycles. Of the nine patients who did not
complete six cycles (Supplementary Table 1), five had five cycles of
chemotherapy, one had disease progression after four cycles, one
stopped after three cycles due to chest infection and two stopped
after one cycle (one due to dehydration/anaemia and the other
anaphylaxis to paclitaxel).
Seventy eight percent (36/46) completed four to six cycles of
cisplatin therapy during CRT (Supplementary Table 2). Five
patients had three cycles and one patient had one cycle. The six
patients who stopped cisplatin before cycle 4, did so because of
toxicity (n¼ 3) and unspecified reason (n¼ 3). The toxicities were:
haematological and abdominal pain/nausea/vomiting (n¼ 1) and
tinnitus with or without palpitation (n¼ 2). Three patients did not
start cisplatin due to disease progression (n¼ 1), dehydration and
anaemia (n¼ 1) and allergic reaction (n¼ 1). Four patients had a
cisplatin dose reduction, because of haematological toxicity (n¼ 1)
and clinical reasons (n¼ 3: COPD exacerbation, low creatinine
clearance and weight change). Twenty patients had a treatment
delay during CRT, mainly due to toxicity (n¼ 10), clinician/patient
decision (n¼ 3) or administrative/logistical/other reasons (n¼ 9).
Ninety eight percent (45/46) of patients had radiotherapy
(Supplementary Table 3); one patient had an adenosquamous
tumour and the disease (local and PALN) progressed on NACT.
Ninety six percent had brachytherapy and 67% had a boost to the
pelvic sidewall. Four of the five patients with positive PALN
received extended field radiation as per protocol (one patient
progressed after four cycles of NACT and was not given any
further treatment). Most patients who had brachytherapy, received
a dose of 15Gy in two fractions HDR (30/44), and 10 patients had
X21Gy in one fraction LDR and one 27Gy in MDR.
Efficacy. The proportion who had a complete/partial response was
70% (32/46; 95% CI: 54–82), at the end of NACT, and 85% (39/46;
95% CI: 71–94), 12 weeks after completing CRT (Table 3). A
complete response was seen in two women after NACT and in 29
patients 12 weeks after finishing CRT. The proportion of patients
with stable disease after NACT and CRT was 22% (10/46) and 4%
(2/46), respectively. Two patients (4%) progressed after NACT, one
of whom had no further treatment because of rapidly progressing
disease. The other had stable disease in the primary tumour but
developed new nodal disease and progressed further after CRT.
One patient progressed after CRT.
Kaplan–Meier plots for PFS and OS are shown in Figure 1.
There were 14 events for PFS (4 with disease progression and 10
deaths), and the rates at 6 months and 1 year were 89% (95% CI:
76–95) and 80% (95% CI: 66–89), and at both 3 and 5 years were
68% (95% CI: 51–79).
Of the five patients with positive PALN at diagnosis, four
patients completed all six cycles of NACT and three to five cycles
of cisplatin. Three out of these four patients were without any
Table 1. Baseline characteristics
Summary statistics
(Median and range)
Age (years) 43 (23–71)
Weight (kg) 74 (44–106)
Haemoglobin (g dl1) 13 (10–15)
White blood cells (109 per l) 10 (5–19)
Platelets (109 per l) 331 (198–760)
Neutrophils ( 109 per l) 7 (3–15)
N (%)
Cell type
Adenocarcinoma 10 (22)
Adenosquamous 3 (7)
Squamous 33 (72)
Patients with positive para-aortic nodes 5 (11)
FIGO stage
Ib2 5 (11)
IIb 23 (50)
IIIa 2 (4)
IIIb 13 (28)
IVa 3 (7)
Table 2. Compliance to neoadjuvant chemotherapy
Number of patients (%)
N¼46
Number of cycles completed
1 2 (4)
2 0
3 1 (2)
4 1 (2)
5 5 (11)
6 37 (80)
Stopped before six cycles 9 (20)
Reasons
Allergic reaction 2
Toxicitya 4
Disease progression 1
Administrative 1
Not reported 1
Dose delayb 6 (13)
Reasons
Toxicityc 3
Drainage of lymphocyte 1
Dehydration and anaemia (SAE) 2
Dose reduction 4 (9)
Reasons
Toxicityd 3
Poor GFR 1
Abbreviation: GFR¼glomerular filtration rate.
aHaematological toxicity (n¼ 3), chest infection (n¼ 1).
bThere were an additional 10 patients whose treatment was delayed by only 1 day because
of administrative/logistical reasons (these are not counted in the table).
cAllergic reaction (n¼ 1), upper respiratory tract infection (n¼ 1), constipation (n¼ 1).
dAllergic reaction (n¼ 2), haematological toxicity (n¼ 1).
BRITISH JOURNAL OF CANCER A phase II study of weekly NACT followed by CRT
2466 www.bjcancer.com |DOI:10.1038/bjc.2013.230
evidence of disease during follow-up. One patient progressed on
completing four cycles of NACT and died shortly after.
In all, 14 patients had died at the time of analysis: cervical
cancer (n¼ 11), haemorrhage (n¼ 2; 28 days and 7 months
after finishing cisplatin) and cardiac arrest (n¼ 1). The OS rates
at 6 months and 1 year were 91% (95% CI: 78–97), 80% (95% CI:
66–89), and at both 3 and 5 years were 67% (95% CI: 51–79) with
no deaths or progression between 3 and 5 years.
Adverse events. Adverse events according to NCI CTCAE v3.0
and RTOG criteria are summarised in Table 4 and Supplementary
Table 4.
NACT. Relatively few patients experienced a grade 3 or 4 adverse
event during NACT. In all, 20% (9/46) had any type of event, of
which 11% (5/46) were haematological and 9% (4/46) were non-
haematological (Table 4).
CRT. A total of 52% of patients had a grade 3 or 4 adverse event
during CRT. Haematological toxicity accounted for 41% (19/46),
whereas 22% (10/46) had a non-haematological event (Table 4).
Overall treatment and follow-up. In total, 63% (29/46) had grade
3/4 toxicity at any time during treatment (NACT/CRT) or follow-
up. Most were haematological (48%), and the most common non-
haematological events were diarrhoea (13%), vomiting (9%),
Table 3. Tumour response using RECIST criteria
Post-neoadjuvant
N¼46, N (%)
12 Weeks after
all treatment
N¼46, N (%)
Complete response 2 (4) 29 (63)
Partial response 30 (65) 10 (22)
Stable disease 10 (22) 2 (4)
Progressive disease 2 (4) 2 (4)
Assessment not done 2 (4)a 3 (7)b
aOne patient died after cycle 1, and the other had an serious adverse event after starting
treatment so stopped early.
bThe same two patients as above and a third patient due to progressive disease and
clinician’s choice.
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Figure 1. Kaplan–Meier plots for progression-free survival (PFS;
upper) and overall survival (OS; lower) for the 46 patients in the study.
The PFS and OS rates are the same for 3 and 5 years (68% and 67%) as
there were no PFS or OS events between 3 and 5 years.
Table 4. Grade 3 or 4 adverse events (classified according to NCI CTCAE
v3.0 and RTOG criteria), based on the worst grade for each patient and
each type of toxicity
No. of
patients (%)
During
neoadjuvant
therapy
N¼46
During
chemoradiation
N¼46
At any time
(including
follow-up)
N¼46
Toxicity
Grade
3
Grade
4
Grade
3
Grade
4 Grade 3/4
Anaemia 1 (2) 0 1 (2) 0 4 (9)
Neutropenia 3 (7) 1 (2) 14 (30) 0 16 (35)
Thrombocytopenia 0 0 7 (15) 1 (2) 9 (20)
Any
haematological
toxicitya
4 (9) 1 (2) 17 (37) 2 (4) 22 (48)b
Constipation 1 (2) 0 0 0 1 (2)
Hypersensitivity 1 (2) 1 (2) 0 0 2 (4)
Diarrhoea 1 (2) 0 6 (13) 0 6 (13)
Nausea 0 0 1 (2) 0 3 (7)
Vomiting 1 (2) 0 3 (7) 0 4 (9)
Peripheral
neuropathy
0 0 0 0 1 (2)
Rash 0 0 1 (2) 0 1 (2)
Renal 0 0 1 (2) 0 2 (4)
Infection (not
neutropenic)
1 (2) 0 0 0 3 (7)
Any non-
haematological
toxicitya
3 (7) 1 (2) 10 (22) 0 15 (33)
RTOG-criteria
Intestines 0 0 0 0 1
Bladder 0 0 0 0 0
Skin 0 0 0 0 0
Subcutaneous
tissue
0 0 0 0 0
Other 0 0 0 0 1c
Any RTOG-criteria
toxicitya
0 0 2 (4)
Any toxicitya 7 (15) 2 (4) 22 (48) 2 (4) 29 (63)
There were no grade 3 or 4 events for anorexia, myalgia or alopecia.
aEach patient only counted once.
bTwenty patients with grade 3, and five patients with grade 4.
cRecto-vaginal fistula (grade 3).
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nausea (7%) and infection (7%). There were two reported
suspected unexpected serious adverse reactions, confusion and
pulmonary embolism, both considered by the treating clinician to
be possibly related to cisplatin and carboplatin. 35% (16/46) had at
most a grade 2 adverse event at any time during treatment or
follow-up (Supplementary Table 4), 28% (13/46) of which were
haematological. Other events included constipation, nausea, and
alopecia. 39% (18/46) had a grade 2 RTOG toxicity recorded
during follow up (Supplementary Table 4).
DISCUSSION
The CxII trial used a novel approach of administering weekly
carboplatin and paclitaxel chemotherapy for six weeks followed
immediately by standard CRT commencing in week seven. The
results from this trial confirm that a short course of dose-dense
weekly NACT with carboplatin and paclitaxel, followed by radical
CRT, is feasible with acceptable toxicity. The response rate to this
short course of chemotherapy, as assessed radiologically within
days of completing the sixth week, was 70% with an 85% overall
response rate after CRT, and an OS rate of 67% at 3 years. Three
out of the 5 patients with positive PALN were alive with no
evidence of disease at the time of analysis. This approach may have
particular merits in this patient population.
Previous trials investigating the role of NACT in cervical cancer
have used a variety of different drugs with different schedules and a
gap of up to 28 days in some trials between the completion of
chemotherapy and the start of definitive radiotherapy. Both the
protracted schedules and the gap between completing chemother-
apy and radiotherapy are likely to have contributed to tumour cell
repopulation thereby limiting the effectiveness of the additional
chemotherapy (Kim and Tannock, 2005). Therefore strategies to
limit this process may lead to an improvement in outcome.
Dose dense NACT is a feasible approach as it did not
compromise chemoradiotherapy with 98% of patients completing
the radiation phase within 50 days and 78% receiving at least
4 cycles of concomitant cisplatin, whilst 50% (23/46) received at
least 5 cycles of cisplatin. A retrospective analysis of GOG trials by
Monk et al (2007) showed that up to 50% of patients failed to complete
6 cycles of cisplatin with no apparent difference in OS between those
completing 5 or more cycles. In the current study 50% of patients
completed 5 or more cycles, similar to that recorded in the study by
Rose et al (1999). More recently the meta-analysis of 18 randomised
trials of chemoradiotherapy found no evidence that the effect of CRT
was influenced by cycle length or dose intensity of cisplatin used
(CCCMAC-Chemoradiotherapy for Cervical Cancer Meta-analysis
Collaboration, 2008). Trials using short cycle-chemotherapy appears to
be associated with an improvement in survival compared with those
using a more prolonged cycle interval (NCLACCM-Neoadjuvant
Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis
Collaboration, 2003).
In general NACT was well tolerated with only 20% of patients
experiencing any grade 3/4 event and no treatment-related deaths.
The G3/4 neutropenia rate of 9% in the current study compares
favourably with the 7% observed in the Mori et al (2008) but is
lower than the 15% reported by Duen˜as-Gonza˜lez et al (2003). The
corresponding G2 neutropenia rates were 13%, 16.7% and 16.2% in
the current study, Mori et al (2008) and Duen˜as-Gonza´lez et al
(2003), respectively. The current study confirms the observation by
Mori et al that most adverse events during NACT were G1/2
alopecia and gastrointestinal symptoms.
There were more adverse events during CRT with 41% of patients
having any grade 3/4 haematological toxicity. The grade 3/4
leucopenia rate during CRT in our trial was 33% (data not shown)
whilst the grade 3 neutropenia rate was 30% which is considerably
higher than the 6% reported by Duen˜as-Gonza´lez et al (2003) and
Duen˜as-Gonzalez et al (2011) but comparable to that recorded for
cisplatin and radiation (23%) by Rose et al (1999). Thus the
incorporation of additional chemotherapy into the standard treatment
regimens is likely to result in increased toxicity. Ongoing phase III
trials will provide valuable information on overall toxicity and efficacy
in relation to the timing of additional chemotherapy. In the
INTERLACE trial (ClinicalTrials.gov NCT01566240), the aim is to
investigate whether dose dense weekly chemotherapy (paclitaxel/
carboplatin) for 6 weeks before standard CRT (using cisplatin)
improves OS compared with CRT alone. The OUTBACK trial
(ClinicalTrials.gov NCT01414608) is examining the role of adjuvant
chemotherapy (4 cycles of carboplatin and paclitaxel) after standard
CRT (using cisplatin) against standard CRT alone.
The observed response rate after NACT (70%) in this study is
lower than that reported in other studies of NACT but this may
reflect differences in patient selection, timing and method of
assessment and the number of patients who actually received the
NACT. Park et al (2009) noted a response rate of 91% (assessed
clinically and radiologically 10 days post treatment) in women with
FIGO Ib2-IIb treated with 3 cycles of 10-day cisplatin and paclitaxel
prior to surgery. Similarly, Mori et al (2008) reported a response rate
of 87% in 30 patients (all of whom completed all 6 weeks of NACT,
compared to 80% in our trial) with FIGO stage Ib2-IVa treated with
6 weeks of carboplatin and paclitaxel prior to surgery. Patients with
stage III/IVa disease comprised 39% of those treated in CXII
compared with 16% in the Mori et al (2008) study. Duen˜as-Gonza´lez
et al (2003) reported response rates of 95% in 43 patients with FIGO
Ib2- IIIb disease treated with 3 cycles of 3-weekly carboplatin and
paclitaxel chemotherapy prior to radical hysterectomy and CRT.
However in that study, response was assessed clinically (we used
MRI) and the planned dose of chemotherapy was higher.
In our trial 10 patients (22%) had stable disease at the end of
NACT and 4 of these patients subsequently died from their disease.
Stable disease post-NACT has also been identified by others as a
poor prognostic sign (Park et al, 2009). The overall response rate to
treatment in the present study (complete and partial response) was
85% at 12 weeks post-CRT, and the 3-year PFS and OS rates were
68 and 67% respectively. This is better than the 56% seen in historical
controls (population based audit of outcome from 42 UK centres) in
this patient population in the UK (Vale et al, 2010). The PFS rates in
the current study were comparable to those reported for CRT alone
by Duen˜as-Gonza´lez et al (2011) study (68% vs 65%) but marginally
lower than that reported for the arm with additional chemotherapy
given both with and following radiation 68% vs 74%). These
differences may be explained by differences in patient selection (CxII
included patients with positive PA lymph nodes) and the lower
radiation dose in the current study. The recently launched phase III
trial (INTERLACE) has mandated a higher radiation dose in line with
that used in the Duenaz- Gonzalez study.
In summary, this trial has demonstrated a good response rate to
NCAT followed by CRT in women with locally advanced cervical
cancer. These results have been used to design an international
randomised multicentre phase III trial, INTERLACE to determine
whether this treatment strategy leads to a significant improvement
in survival compared to standard CRT.
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